Skip to main content
. 2014 May 2;55(5):2935–2940. doi: 10.1167/iovs.14-13980

Figure 2.

Figure 2

Subgroup analysis of longitudinal BSCVA in a subset of participants from the SCUT Trial. The predicted means and 95% CIs are shown, stratified by (A) enrollment visual acuity, (B) causative organism, (C) presence of cataract at the 4-year follow-up visit, and (D) treatment allocation in SCUT (steroids versus placebo).